American Biogenics Inc., of Copiague, N.Y., completedan $8.5 million private financing of convertibledebentures. Among earmarked uses for the proceeds isfunding commercial development of the company'sThrombus Precursor Protein test for detection of activethrombosis.

Matritech Inc., of Cambridge, Mass., said its premarketapproval application for the NMP22 Test Kit for bladdercancer will be reviewed Nov. 30, 1995, by an FDAadvisory panel.

Oncor Inc., of Gaithersburg, Md., said its premarketapproval application for the in vitro diagnostic genetictest system for HER-2/neu will be reviewed Nov. 30,1995, by an FDA advisory panel.

* Ostex International Inc., of Seattle, entered into anagreement with SmithKline Beecham ClinicalLaboratories, of Philadelphia, to market and sell itsOsteomark test, which measures human bone loss, in theU.S.

* Glyco Biomedical Ltd., of Novato, Calif., was awardedtwo grants totaling $127,000, one that will enable thecompany to expand indications for its lysosomal diseasediagnostic and one to explore a test for AZT resistance inHIV patients.

* AndCare Inc., of Research Triangle Park, N.C.,received research awards of $170,000 from the U.S.Army and U.S. Navy to research and develop portablebiosensors to detect bacterial or viral agents in humans.

(c) 1997 American Health Consultants. All rights reserved.